Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Dhwani Haria"'
Autor:
Preeti Lal, Jina Lee, Dhwani Haria, Jayamary Divya Ravichandar, Jill Desnoyer, Sabina Lau, Erica Rutherford, Karim Dabbagh, Helena Kiefel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/9b777755354a4abaa12700cd0b57a9a6
Autor:
Dhwani Haria, Jina Lee, Justy Guagua, Archana Nagaraja, Kyle Roskamp, Bum-Yeol Hwang, Divya Ravichandar, Michi Willcoxon, Todd DeSantis, Karim Dabbagh, Helena Kiefel
Publikováno v:
Cancer Research. 82:6349-6349
Immune-checkpoint inhibitor (ICI) therapy releases the molecular “brakes” on the immune system thereby promoting robust anti-tumor immune responses. However, many patients do not respond to ICI therapy due to development of primary and secondary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56ca9e452a88985e89efd977d09b498e
https://doi.org/10.1158/1538-7445.am2022-6349
https://doi.org/10.1158/1538-7445.am2022-6349
Autor:
Michelle Lin, Archana S. Nagaraja, Dhwani Haria, Yuliya Katlinskaya, Divya Ravichandar, Preston Williams, Roberta Hannibal, Todd Z. DeSantis, Bum-Yeol Hwang, Michi Wilcoxon, Toshi Takeuchi, Karim Dabbagh, Preeti Lal, Helena Kiefel
Publikováno v:
Molecular Cancer Therapeutics. 20:P260-P260
The gut microbiome is an important determinant for the success of anti-tumor therapies including chemotherapeutics and anti-checkpoint inhibitors. In this study we wanted to leverage Second Genome’s large and curated microbiome database coupled wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::545aad170f8527476cf17271b82f56e2
https://doi.org/10.1158/1535-7163.targ-21-p260
https://doi.org/10.1158/1535-7163.targ-21-p260
Autor:
Karim Dabbagh, Erica Rutherford, Preeti Lal, Sabina Lau, Jina Lee, Jayamary Divya Ravichandar, Jill Desnoyer, Helena Kiefel, Dhwani Haria
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundDespite the unprecedented clinical success of immune checkpoint therapy (ICI) in many cancers there is still a large unmet need since many patients have an inadequate response. Fecal Matter Transplant from anti-PD-1 responding subjects into
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27ed9a87e20e7efe6f80a4d77ea4a433
https://doi.org/10.1136/jitc-2021-sitc2021.569
https://doi.org/10.1136/jitc-2021-sitc2021.569
Autor:
Karim Dabbagh, Divya Ravichandar, Dhwani Haria, Kareem Graham, Sunit Jain, Todd Z. DeSantis, Yuliya V. Katlinskaya, Shoko Iwai, Thomas Weinmaier, Toshi Takeuchi, Helena Kiefel
Publikováno v:
Cancer Research. 80:B28-B28
The composition of the gut microbiota affects cancer development, progression, and response to therapy. A number of commensal bacteria, including Bifidobacterium, have been associated with increased response to immune checkpoint inhibitors in mouse t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec0ce24b29812b6567ed7987a96c9504
https://doi.org/10.1158/1538-7445.mel2019-b28
https://doi.org/10.1158/1538-7445.mel2019-b28
Autor:
Joanna Catherine Ceolane Dreux, Dhwani Haria, Paul Michäel Loriaux, Shoko Iwai, Yonggan Wu, Todd Z. DeSantis, Helena Kiefel, Michelle I. Lin, Bernat Baeza-Raja, Jayamary Divya Ravichandar, Jill Desnoyer, Karim Dabbagh, Lynn Yamamoto, Erica Rutherford, Toshihiko Takeuchi, Jina Lee, Ashil Bans, Michi Wilcoxon, Sabina Lau, Nicole R. Narayan, Eskedar Nigatu, Cheryl-Emiliane T. Chow
Publikováno v:
Cancer Research. 80:PR08-PR08
The gut microbiota has emerged as an important player in cancer pathology, and increasing evidence supports its role in clinical response to immune checkpoint inhibitor (ICI) therapy. However, the specific microbiome-derived factors responsible for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f17e6ccaaf8a2a333d3f96e5a8db340
https://doi.org/10.1158/1538-7445.mvc2020-pr08
https://doi.org/10.1158/1538-7445.mvc2020-pr08
Autor:
Helena Kiefel, Dhwani Haria, Yuliya Katlinskaya, Divya Ravichandar, Lily McLaughlin, Sunit Jain, Thomas Weinmaier, Shoko Iwai, Todd DeSantis, Toshi Takeuchi, Karim Dabbagh, Kareem Graham
Publikováno v:
Cancer Research. 79:4963-4963
The composition of the gut microbiota affects cancer development, progression, and response to therapy. A number of commensal bacteria, including Bifidobacterium, have been associated with increased response to immune checkpoint inhibitors in mouse t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53f1301e80a6390b870a6ec93ffb9a0c
https://doi.org/10.1158/1538-7445.am2019-4963
https://doi.org/10.1158/1538-7445.am2019-4963
Autor:
Toshi Takeuchi, Yuliya V. Katlinskaya, Anu Hoey, Helena Kiefel, Dhwani Haria, Todd Z. DeSantis, Kareem Graham, Thomas Weinmaier, Lily McLaughlin, Karim Dabbagh, Shoko Iwai, Sunit Jain
Publikováno v:
Cancer Research. 79:576-576
The microbiome shapes the metabolic and immunological landscape of individuals in health and disease and represents a new robust source of bioactive molecules with therapeutic potential. Second Genome’s large and curated microbiome database coupled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::386d00717014a325b61370c721f6493d
https://doi.org/10.1158/1538-7445.am2019-576
https://doi.org/10.1158/1538-7445.am2019-576
Autor:
Todd Z. DeSantis, Shoko Iwai, Toshi Takeuchi, Thomas Weinmaier, Helena Kiefel, Kareem Graham, Yuliya V. Katlinskaya, Dhwani Haria, Sunit Jain, Karim Dabbagh
Publikováno v:
Cancer Research. 79:1490-1490
The gut microbiome is a key contributor to the maintenance of host physiology. At the same time, increasing evidence implicates microbiome dysbiosis as a key determinant of numerous metabolic and inflammatory disorders. It is, therefore, of paramount
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed409a2e912b2de0e8f940f865486100
https://doi.org/10.1158/1538-7445.am2019-1490
https://doi.org/10.1158/1538-7445.am2019-1490
Autor:
Todd Bartkowiak, K. Jagannadha Sastry, Guojun Yang, Shailbala Singh, Michael A. Curran, Dhwani Haria, Midan Ai, James P. Allison, G Galvan
Publikováno v:
Proceedings of the National Academy of Sciences. 112
Antibody modulation of T-cell coinhibitory (e.g., CTLA-4) or costimulatory (e.g., 4-1BB) receptors promotes clinical responses to a variety of cancers. Therapeutic cancer vaccination, in contrast, has produced limited clinical benefit and no curative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf351df9a34ccafe73232d0a41bd0956
https://doi.org/10.1073/pnas.1514418112
https://doi.org/10.1073/pnas.1514418112